Table IV.
Clinical level of evidence of commercially available demineralised bone matrix (DBM)
| Products | Spine surgery | Trauma surgery | Orthopaedic surgery | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Lumbar | Cervical | Thoracic | Acute fractures | Nonunions | Arthrodesis | Avascular necrosis | Reconstructive surgery | Tumour surgery | |
| Accell Connexus (Citagenix, Laval, Canada) | Ext: II14 | ||||||||
| Accell TBM (Integra, Irvine, California) | |||||||||
| AlloCraft (Stryker, Mahwah, New Jersey) | |||||||||
| Allomatrix (Wright Medical, London, United Kingdom) | Ext: III15, Ext: IV16 | *Sub: I17, Sub: IV18-20 | Ext: IV21, Sub: IV22,23 | Ext: IV24 | Ext: IV25,26 | Ext: IV27, Sub: IV23,28,29 | |||
| AlphaGRAFT (Alphatech, Carlsbad, California) | |||||||||
| Altiva (Exactech, Gainesville, Florida) | |||||||||
| BioSet (Penta Biomedical, Verona, Italy) | |||||||||
| DBX (DePuy Synthes, Zuchwil, Switzerland) | Sub: IV30,31 | Sub: IV32 | Sub: IV33,34 | ||||||
| Grafton DBM (Osteotech, Eatontown, New Jersey) | Ext: I35, Ext: II36, Ext: III37, Ext: IV38-40 | *Ext: I41, Ext: IV42-44, Sub: IV45 | Sub: III46 | Ext: II47, Ext: III48, Ext: IV21,49-52 | Ext: II47, Ext: III53, Ext: IV21, Sub: III54, Sub: IV49 | Ext: IV55,56 | Ext: IV57 | Ext58 | Ext: IV59, Sub: IV60-62 |
| InterGro (Zimmer Biomet, Westminster, California) | |||||||||
| Optefil (Exactech) | |||||||||
| Opteform (Exactech) | |||||||||
| Optium DBM (DePuy. Warsaw, Indiana) | |||||||||
| OrthoBlast (Citagenix) | Ext: III48, Ext: IV49 | Ext: IV55 | |||||||
| OrthoBlast II (Citagenix) | |||||||||
| Osteofil (Medtronic, Minneapolis, Minnesota) | Ext: IV63 | Ext: IV64 | |||||||
| VIAGRAF (Smith & Nephew, London, United Kingdom) | |||||||||
Information presented as bone graft type followed by level of evidence number as described by Wright et al10
*
DBM performance inferior to that of control group used
Ext, bone graft extender; Sub, bone graft substitute